Search Results

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Intercept Pharmaceuticals, Inc. is presenting two new sub-analyses from its Phase 3 POISE study in primary biliary cholangitis (PBC), at Digestive Disease Week® (DDW) 2024 in Washington, D.C.

Intercept Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva for the treatment of individuals with primary biliary cholangitis (PBC).

Intercept Pharmaceuticals, Inc. announced new sub-analyses from its Phase 3 POISE trial in primary biliary cholangitis showing the effect of obeticholic acid across a number of key biomarkers of liver health in people living with PBC will be presented at the European Association for the Study of the Liver Congress 2024 being held June 5-8, 2024, in Milan, Italy.

Intercept Pharmaceuticals, Inc. today announced new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating the combination of obeticholic acid (OCA) and bezafibrate in patients with primary biliary cholangitis (PBC) at the European Association for the Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024, in Milan, Italy.

MAPS Public Benefit Corporation (“MAPS PBC”) announced the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider.